Global patterns of prescription pain medication usage in disorders of gut-brain interactions.
Yuying LuoSuzi A CameyShrikant I BangdiwalaOlafur S PalssonAmi D SperberLaurie A KeeferPublished in: Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society (2022)
14.8% of patients globally with at least one diagnosis of DGBI were on prescription pain medications with wide geographic variation, about twice as many as their counterparts without a diagnosis of DGBI. Environmental, sociodemographic, and individual factors may influence clinicians to consider personalized, multimodal approaches to address pain in patients with DGBI.
Keyphrases
- chronic pain
- pain management
- neuropathic pain
- end stage renal disease
- ejection fraction
- chronic kidney disease
- newly diagnosed
- healthcare
- palliative care
- emergency department
- prognostic factors
- resting state
- white matter
- peritoneal dialysis
- multiple sclerosis
- patient reported outcomes
- spinal cord injury
- functional connectivity
- blood brain barrier